| Literature DB >> 29267612 |
Ana Paula Susin Osório1, Stefan Warpechowski1, Antonio Lessa Gaudie Ley1,2, Marcelo Haertel Miglioranza1, Laura Lessa Gaudie Ley1,2, Eduardo Dytz Almeida1, Roberto Tofani Sant'anna1, Tiago Luiz Luz Leiria1.
Abstract
INTRODUCTION: Chronic stimulation of the right ventricle with pacemaker is associated with ventricular dyssynchrony and loss of contractility, even in subjects without previous dysfunction. In these patients, there is a debate of which pacing site is less associated with loss of ventricular function.Entities:
Mesh:
Year: 2017 PMID: 29267612 PMCID: PMC5731315 DOI: 10.21470/1678-9741-2017-0056
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Clinical and pacing echocardiographic characteristics (n=40).
| Variables | N (%) or mean ± SD |
|---|---|
| Age | 69.25±14.76 years |
| Male | 22 (55%) |
| BMI | 27.91±4.78 |
| Heart rate (bpm) | 71.15±9.78 |
| QRS in lead DII during echo (ms) | 93.68±15.72 |
| Largest QRS on 12 lead ECG | 148.97±15.52 |
| Hypertension | 26 (65%) |
| DM | 10 (25%) |
| Dyslipidemia | 13 (32%) |
| Smoking | 13 (32.5%) |
| CAD | 6 (15%) |
| NYHA functional class | |
| I | 87.5% |
| II | 12.5% |
| Current medications | |
| Diuretics | 15 (37.5%) |
| ACE inhibitors | 12 (30%) |
| Angiotensin receptor blockers | 11 (27.5%) |
| Beta-blockers | 20 (50%) |
| Calcium channel blockers | 5 (12.5%) |
| Amiodarone | 1 (2.5%) |
| Reason for the Implant | |
| Complete AV block | 25 (62.5%) |
| 2nd degree AV block | 7 (17.5%) |
| Others | 8 (20%) |
| Stimulation Mode | |
| DDD | 29 (72.5%) |
| DDDR | 6 (15%) |
| VVIR | 4 (10%) |
| VDD | 1 (2.5%) |
| RV pacing (%) | 94.95%±10.65% |
Bpm=beats per minute; ms=milliseconds; DM=diabetes mellitus; CAD=coronary artery disease; NYHA=New York Heart Association; ECG=electrocardiography; ACE=angiotensin enzyme converter, BMI= body mass index; AV=atrioventricular; RV=right ventricle
Echocardiographic measurements of ventricular synchrony, in milliseconds.
| Ventricular Synchrony Measurements | Mean ± SD |
|---|---|
| Aortic pre-ejection time | 140.60±22.52 |
| Pulmonary pre-ejection time | 98.33±22.12 |
| Interventricular delay | 43.27±20.25 |
| Septum/posterior wall delay (M mode) | 105.50±46.9 |
| Diastolic volume of LV (ml) | 91.68±29.08 |
| Systolic volume of LV (ml) | 34±13.10 |
| Ejection fraction (%) | 63.50±6.09 |
| Left atrial volume (ml) | 32.12 ±10.24 |
| Ratio E/e' | 11.11±4.50 |
LV=left ventricle
Fig. 1QRS on lead DII during echocardiogram (ms).
RVFW=Right ventricle free wall; RVMS=Right ventricle medium septum
Fig. 2Largest QRS on 12 lead ECG (ms).
RVFW=right ventricle free wall; RVMS=right ventricle medium septum
Fig. 3QRS duration and aortic pre-ejection time.
Fig. 4QRS duration and interventricular delay.
Fig. 5New York Heart Association class and lead position.
NYHA=New York Heart Association; RVFW=right ventricle free wall; RVMS=right ventricle medium septum
Fig. 6Intraventricular delay and lead position.
IV=interventricular; RVFW=right ventricle free wall; RVMS=right ventricle medium septum
Fig. 7Aortic pre-ejection time and pulmonary pre-ejection time according to pacing site.
Fig. 8Interventricular dyssynchrony and pacing position.
| Abbreviations, acronyms & symbols | |
|---|---|
| ACE | = Angiotensin enzyme converter |
| AF | = Atrial fibrillation |
| CAD | = Coronary artery disease |
| DM | = Diabetes mellitus |
| ECG | = Electrocardiography |
| HF | = Heart failure |
| LVEF | = Left ventricular ejection fraction |
| NYHA | = New York Heart Association |
| RV | = Right ventricle |
| RVFW | = Right ventricle free wall |
| RVMS | = Right ventricle medium septum |
| RVOT | = Right ventricle outflow tract |
| Authors' roles & responsibilities | |
|---|---|
| APSO | Actively participated of literature review, article review, interpretation of results and approved the final version; performed the echocardiographic evaluation; final approval of the version to be published |
| SWN | Actively participated of literature review, article review, interpretation of results and approved the final version; final approval of the version to be published |
| ALGL | Actively participated of literature review, article review, interpretation of results and approved the final version; final approval of the version to be published |
| MHM | Actively participated of literature review, article review, interpretation of results and approved the final version; final approval of the version to be published |
| LLGL | Actively participated of literature review, article review, interpretation of results and approved the final version; final approval of the version to be published |
| EDA | Actively participated of literature review, article review, interpretation of results and approved the final version; final approval of the version to be published |
| RTS | Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| TLLL | Acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |